ANXIOLYTIC PROPERTY

Nature has provided humans with medicine, shelter, food, clothing, fragrances, and transportation throughout history. The D3 organic® supplement's antidepressant and anxiolytic properties are assessed. Antidepressants and anxiolytics were tested in the forced swim, tail suspension, and elevated plus maze. Twenty-five 20–30 gram mice were divided into five groups of five. Group 1 received 10 ml/kg distilled water, Groups 2, 3, and 4 received 50, 100, and 200 mg/kg D3 organic® supplement extract, and Group 5 received 20 mg/kg oral fluoxetine. After receiving D3 and fluoxetine, mice were placed in an unbreakable transparent cylinder filled with water at 25°C for one hour. Animal immobility was measured after 5 minutes of swimming. Twenty 20–30 gram mice were randomly assigned to five four-animal groups. Group 1 received distilled water (10 ml/kg), groups 2–4 D3 organic® supplement extract (50, 100, and 200 mg/kg), and group 5 diazepam. The animals spent five minutes in the central maze an hour after receiving D3 organic® supplement extracts and diazepam. The number of entries and open arms time were recorded. In the forced swimming and tail suspension test, D3 organic® supplement extract (100 and 200 mg/kg) and fluoxetine (20 mg/kg) reduced immobility time compared to the control (p<0.05). Diazepam (10 mg/kg) and D3 organic® supplement extract (100 and 200 mg/kg) increased time spent and percentage time spent in the open arm compared to the control (p<0.05). D3 Organic® Supplement has anxiolytic and antidepressant properties.

Background: Alzheimer's disease represents a progressive neurodegenerative disorder characterized by substantial cognitive deterioration and frequently accompanied by behavioral manifestations, particularly anxiety. While contemporary therapeutic interventions predominantly target cognitive deficits, they inadequately address anxiety related symptoms. This investigation examined the neurotherapeutic potential of Ritonavir (a protease inhibitor) within an aluminum chloride (AlCl3) - induced model of Alzheimer's disease, focusing specifically on its anxiolytic properties and capacity to modulate APOE4 gene expression.
Objective: The primary objective was to evaluate the anxiolytic efficacy and molecular regulatory effects of Ritonavir across multiple dosing regimens (100, 200, and 400mg/kg) in disease-model mice, comparing its therapeutic profile against Donepezil and control groups. Methods: Fifty-six mice underwent randomized allocation into seven experimental cohorts. Anxiety-related behaviors were assessed using the Elevated Plus Maze paradigm, while exploratory tendencies were quantified via the Hole Board Test. Hippocampal APOE4 gene expression patterns were determined through quantitative real-time polymerase chain reaction (RT-qPCR) methodology. Results: Behavioral assessments demonstrated that the highest Ritonavir concentration
(400mg/kg) produced significant anxiolytic effects in the Elevated Plus Maze, evidenced by increased open-arm exploration duration (p < 0.05) relative to AlCl₃-induced disease controls. This dosage exhibited comparable efficacy to Donepezil. Furthermore, the 400mg/kg cohort demonstrated enhanced exploratory behavior in the Hole Board assessment. Molecular analysis revealed that Ritonavir 400mg/kg effectively normalized APOE4 transcriptional levels toward baseline parameters, demonstrating statistical superiority over lower concentrations and the reference medication (p < 0.05). Conclusion: Ritonavir at 400mg/kg exhibits robust anxiolytic properties coupled with favorable APOE4 gene expression modulation, suggesting potential utility as a dual-mechanism therapeutic agent capable of addressing both behavioral symptomatology and molecular pathogenesis in Alzheimer's disease.